According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Other analysts have also recently issued reports about the stock. Oppenheimer restated a buy rating and issued a $7.00 price target on shares of Seres Therapeutics in a report on Tuesday, July 28th. Chardan Capital restated a market perform rating and issued a $12.50 price target on shares of Seres Therapeutics in a report on Thursday, June 25th. Canaccord Genuity restated a buy rating and issued a $11.00 price target on shares of Seres Therapeutics in a report on Friday, May 8th. BidaskClub cut shares of Seres Therapeutics from a buy rating to a hold rating in a report on Saturday, July 18th. Finally, ValuEngine lowered shares of Seres Therapeutics from a buy rating to a hold rating in a research report on Thursday, July 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. Seres Therapeutics has a consensus rating of Hold and a consensus target price of $8.70.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $6.05 million for the quarter, compared to analyst estimates of $9.67 million. As a group, equities research analysts forecast that Seres Therapeutics will post -0.81 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Citigroup Inc. raised its position in shares of Seres Therapeutics by 15.0% in the 1st quarter. Citigroup Inc. now owns 15,802 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 2,060 shares during the last quarter. Federated Hermes Inc. raised its position in Seres Therapeutics by 160.0% during the 1st quarter. Federated Hermes Inc. now owns 1,028,800 shares of the biotechnology company’s stock worth $3,673,000 after buying an additional 633,135 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in Seres Therapeutics by 162.4% during the 1st quarter. BNP Paribas Arbitrage SA now owns 11,351 shares of the biotechnology company’s stock worth $41,000 after buying an additional 7,025 shares during the last quarter. FDx Advisors Inc. purchased a new position in Seres Therapeutics during the 2nd quarter worth approximately $49,000. Finally, Two Sigma Advisers LP raised its position in Seres Therapeutics by 15.1% during the 1st quarter. Two Sigma Advisers LP now owns 89,300 shares of the biotechnology company’s stock worth $319,000 after buying an additional 11,700 shares during the last quarter. 93.39% of the stock is owned by hedge funds and other institutional investors.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Read More: Cost of Debt
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.